Liposomal Daunorubicin in Treating Patients With HIV-Related Kaposi's Sarcoma

Stopped early · Phase 1

Conditions studied: Sarcoma

In brief

RATIONALE: Drugs used in chemotherapy, such as liposomal daunorubicin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. PURPOSE: This clinical trial is studying how well liposomal daunorubicin works in treating patients with HIV-related Kaposi's sarcoma.

Key facts

Study ID

NCT00427414

Run by

AIDS Malignancy Consortium

People needed

14

Starts

2008-09-01

Expected to finish

2011-11-01

Last updated by the study team

2015-04-29

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• University of Miami Sylvester Comprehensive Cancer Center - Miami — Miami, Florida, United States
• Centro de Referencia e Tratamento DST/AIDS — São Paulo, São Paulo, Brazil
• Instituto De Infectologia Emilio Ribas Hospital — Cerqueira Cesar - Sao Paulo/SP, Brazil

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.